These findings suggest that LFA-1 contributes to a pro-tumorigenic microenvironment by promoting Treg cell-mediated immune suppression, drawing attention to its potential as a therapeutic target for cancer immunotherapy. This evidence concerns the gene ITGB2 and cancer.